Global Glucagon-like Peptide 1 (GLP-1) Market: Analysis By Product (Trulicity, Ozempic, Victoza, Rybelsus and Other GLP 1 Products), By Route of Administration (Injectable and Oral Medication), By Region Size and Trends with Impact of COVID-19 and Forecast up to 2027
GLP-1 receptor agonists are a type of non-insulin medication used to treat type 2 diabetes in conjunction with diet and exercise. These medications are used to help lower blood glucose levels and hemoglobin A1C, as well as to aid in weight loss. GLP-1 signals the hypothalamus, the part of the brain in charge of appetite and thirst, to consume less water and food. In 2021, the global glucagon-like peptide 1 (GLP-1) market was valued at US$16.53 billion, and is probable to reach US$24.10 billion by 2027.
The market would gain traction in the upcoming years with an increase in the number of products approved that help with the treatment of diabetes. It is anticipated that an increase in mergers and acquisitions would support the market in the coming years. The glucagon-like peptide 1 (GLP-1) market is projected to grow at a CAGR of 6.48%, during the forecast period of 2022-2027.
Market Segmentation Analysis:
By Product: According to the report, the global glucagon-like peptide 1 (GLP-1) market is segmented into five products: Trulicity, Ozempic, Victoza, Rybelsus and Other GLP 1 Products. Trulicity product acquired majority of share in the market in 2021, due to increasing prevalence of type 2 diabetes, which has led to a greater demand for effective treatments. Whereas, rybelsus segment is expected to have the highest CAGR in the future due to its effectiveness in lowering blood sugar levels, its convenient once-daily dosing, and the fact that it is taken orally rather than by injection like many other diabetes medications.
By Region: According to this report, the global glucagon-like peptide 1 (GLP-1) market can be divided into five major regions: North America (The US, Canada and Mexico), Asia Pacific (China, Japan, India, Australia South Korea and Rest of Asia Pacific), Europe (Germany, UK, France, Italy, Spain and Rest of Europe), Latin America and Middle East and Africa. The North America glucagon-like peptide 1 (GLP-1) market enjoyed the highest market share in 2021, primarily owing to an increase in the aged population with rising prevalence of diabetes and obesity and high awareness among the population and higher per capita income of the population.
While the US continues to be a prominent region of North America glucagon-like peptide 1 (GLP-1) market, accounting to the prevalence of advanced healthcare technologies, increased funding for research and development activities, increasing incidence of diabetes and growing geriatric population.
Global Glucagon-like Peptide 1 (GLP-1) Market Dynamics:
Growth Drivers: Diabetes prevalence has risen faster in low- and middle-income countries than in high-income countries. As the number of adults diagnosed with diabetes rises, so does the demand for medication, driving the global market for Glucagon-like Peptide 1. (GLP-1). Further, the market is expected to increase due to rising cases of obesity, rapid urbanization, increasing healthcare expenditure, increasing aging population, etc.
Challenges: The major downside of GLP-1 agonists is that they have a shorter half-life due to degradation in the presence of the DPP enzyme. If the half-life is too short, more frequent dosage may be required to maintain acceptable exposures while avoiding unduly high peak concentrations. The other challenge that glucagon-like peptide 1 (GLP-1) market face is limitations related to unknown severe side effects, etc.
Trends: A major trend gaining pace in glucagon-like peptide 1 (GLP-1) market is potential clinical application of GLP-1 receptor agonists for the treatment of NASH. There is some evidence to suggest that GLP-1 (glucagon-like peptide-1) may be a useful treatment for NASH. One study found that treatment with a GLP-1 agonist led to significant improvements in liver function, including reductions in liver fat content, in people with NASH. More trends in the market are believed to augment the growth of glucagon-like peptide 1 (GLP-1) market during the forecasted period include surge in research & development in pharmaceutical sector, new product launches, expanding reimbursement landscape, etc.
Impact Analysis of COVID-19 and Way Forward:
The COVID-19 pandemic has had a complex and multifaceted impact on the market for GLP-1 (glucagon-like peptide-1) drugs, which are used to treat type 2 diabetes by helping to control blood sugar levels. The demand for GLP-1 drugs may have increased as a result of the pandemic due to the high prevalence of diabetes and the associated risk of severe illness or death from COVID-19. People with diabetes are at increased risk of complications from COVID-19, including severe illness and death, and may therefore be more motivated to take their medications as prescribed and to manage their blood sugar levels carefully.
Competitive Landscape and Recent Developments:
The glucagon-like peptide 1 (GLP-1) market is concentrated with the presence of a few number of players majorly dominating worldwide. Key players of the glucagon-like peptide 1 (GLP-1) market are:
The market would gain traction in the upcoming years with an increase in the number of products approved that help with the treatment of diabetes. It is anticipated that an increase in mergers and acquisitions would support the market in the coming years. The glucagon-like peptide 1 (GLP-1) market is projected to grow at a CAGR of 6.48%, during the forecast period of 2022-2027.
Market Segmentation Analysis:
By Product: According to the report, the global glucagon-like peptide 1 (GLP-1) market is segmented into five products: Trulicity, Ozempic, Victoza, Rybelsus and Other GLP 1 Products. Trulicity product acquired majority of share in the market in 2021, due to increasing prevalence of type 2 diabetes, which has led to a greater demand for effective treatments. Whereas, rybelsus segment is expected to have the highest CAGR in the future due to its effectiveness in lowering blood sugar levels, its convenient once-daily dosing, and the fact that it is taken orally rather than by injection like many other diabetes medications.
By Region: According to this report, the global glucagon-like peptide 1 (GLP-1) market can be divided into five major regions: North America (The US, Canada and Mexico), Asia Pacific (China, Japan, India, Australia South Korea and Rest of Asia Pacific), Europe (Germany, UK, France, Italy, Spain and Rest of Europe), Latin America and Middle East and Africa. The North America glucagon-like peptide 1 (GLP-1) market enjoyed the highest market share in 2021, primarily owing to an increase in the aged population with rising prevalence of diabetes and obesity and high awareness among the population and higher per capita income of the population.
While the US continues to be a prominent region of North America glucagon-like peptide 1 (GLP-1) market, accounting to the prevalence of advanced healthcare technologies, increased funding for research and development activities, increasing incidence of diabetes and growing geriatric population.
Global Glucagon-like Peptide 1 (GLP-1) Market Dynamics:
Growth Drivers: Diabetes prevalence has risen faster in low- and middle-income countries than in high-income countries. As the number of adults diagnosed with diabetes rises, so does the demand for medication, driving the global market for Glucagon-like Peptide 1. (GLP-1). Further, the market is expected to increase due to rising cases of obesity, rapid urbanization, increasing healthcare expenditure, increasing aging population, etc.
Challenges: The major downside of GLP-1 agonists is that they have a shorter half-life due to degradation in the presence of the DPP enzyme. If the half-life is too short, more frequent dosage may be required to maintain acceptable exposures while avoiding unduly high peak concentrations. The other challenge that glucagon-like peptide 1 (GLP-1) market face is limitations related to unknown severe side effects, etc.
Trends: A major trend gaining pace in glucagon-like peptide 1 (GLP-1) market is potential clinical application of GLP-1 receptor agonists for the treatment of NASH. There is some evidence to suggest that GLP-1 (glucagon-like peptide-1) may be a useful treatment for NASH. One study found that treatment with a GLP-1 agonist led to significant improvements in liver function, including reductions in liver fat content, in people with NASH. More trends in the market are believed to augment the growth of glucagon-like peptide 1 (GLP-1) market during the forecasted period include surge in research & development in pharmaceutical sector, new product launches, expanding reimbursement landscape, etc.
Impact Analysis of COVID-19 and Way Forward:
The COVID-19 pandemic has had a complex and multifaceted impact on the market for GLP-1 (glucagon-like peptide-1) drugs, which are used to treat type 2 diabetes by helping to control blood sugar levels. The demand for GLP-1 drugs may have increased as a result of the pandemic due to the high prevalence of diabetes and the associated risk of severe illness or death from COVID-19. People with diabetes are at increased risk of complications from COVID-19, including severe illness and death, and may therefore be more motivated to take their medications as prescribed and to manage their blood sugar levels carefully.
Competitive Landscape and Recent Developments:
The glucagon-like peptide 1 (GLP-1) market is concentrated with the presence of a few number of players majorly dominating worldwide. Key players of the glucagon-like peptide 1 (GLP-1) market are:
- Sanofi
- Pfizer Inc.
- AstraZeneca PL
- Eli Lilly and Company
- Novo Nordisk A/S
- Shanghai Benemae Pharmaceutical Corporation
- Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1 Glucagon-like Peptide-1 (GLP-1): An Overview
2.1.1 Definition of Glucagon-like Peptide-1 (GLP-1)
2.1.2 Types of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist
2.2 Glucagon-like Peptide-1 (GLP-1) Segmentation: An Overview
2.2.1 Glucagon-like Peptide-1 (GLP-1) Segmentation
3. GLOBAL MARKET ANALYSIS
3.1 Global Glucagon-like Peptide-1 (GLP-1) Market: An Analysis
3.1.1 Global Glucagon-like Peptide-1 (GLP-1) Market: An Overview
3.1.2 Global Glucagon-like Peptide-1 (GLP-1) Market by Value
3.1.3 Global Glucagon-like Peptide-1 (GLP-1) Market by Product (Trulicity, Ozempic, Victoza, Rybelsus and Other GLP 1 Products)
3.1.4 Global Glucagon-like Peptide-1 (GLP-1) Market by Route of Administration (Injectable and Oral Medication)
3.1.5 Global Glucagon-like Peptide-1 (GLP-1) Market by Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa)
3.2 Global Glucagon-like Peptide-1 (GLP-1) Market: Product Analysis
3.2.1 Global Glucagon-like Peptide-1 (GLP-1) Market by Product: An Overview
3.2.2 Global Trulicity GLP-1 Market by Value
3.2.3 Global Ozempic GLP-1 Market by Value
3.2.4 Global Victoza GLP-1 Market by Value
3.2.5 Global Rybelsus GLP-1 Market by Value
3.2.6 Global Other GLP-1 Products Market by Value
4. REGIONAL MARKET ANALYSIS
4.1 North America Glucagon-like Peptide-1 (GLP-1) Market: An Analysis
4.1.1 North America Glucagon-like Peptide-1 (GLP-1) Market: An Overview
4.1.2 North America Glucagon-like Peptide-1 (GLP-1) Market by Value
4.1.3 North America Glucagon-like Peptide-1 (GLP-1) Market by Region (The US, Canada, and Mexico)
4.1.4 The US Glucagon-like Peptide-1 (GLP-1) Market by Value
4.1.5 The US Glucagon-like Peptide-1 (GLP-1) Market by Route of Administration (Injectable and Oral Medication)
4.1.6 Canada Glucagon-like Peptide-1 (GLP-1) Market by Value
4.1.7 Mexico Glucagon-like Peptide-1 (GLP-1) Market by Value
4.2 Europe Glucagon-like Peptide-1 (GLP-1) Market: An Analysis
4.2.1 Europe Glucagon-like Peptide-1 (GLP-1) Market: An Overview
4.2.2 Europe Glucagon-like Peptide-1 (GLP-1) Market by Value
4.2.3 Europe Glucagon-like Peptide-1 (GLP-1) Market by Region (Germany, The UK, France, Italy, Spain, and Rest of the Europe)
4.2.4 Germany Glucagon-like Peptide-1 (GLP-1) Market by Value
4.2.5 The UK Glucagon-like Peptide-1 (GLP-1) Market by Value
4.2.6 France Glucagon-like Peptide-1 (GLP-1) Market by Value
4.2.7 Italy Glucagon-like Peptide-1 (GLP-1) Market by Value
4.2.8 Spain Glucagon-like Peptide-1 (GLP-1) Market by Value
4.2.9 Rest of Europe Glucagon-like Peptide-1 (GLP-1) Market by Value
4.3 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market: An Analysis
4.3.1 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market: An Overview
4.3.2 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market by Value
4.3.3 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market by Region (China, Japan, India, Australia, South Korea, and Rest of the Asia Pacific)
4.3.4 China Glucagon-like Peptide-1 (GLP-1) Market by Value
4.3.5 Japan Glucagon-like Peptide-1 (GLP-1) Market by Value
4.3.6 India Glucagon-like Peptide-1 (GLP-1) Market by Value
4.3.7 Australia Glucagon-like Peptide-1 (GLP-1) Market by Value
4.3.8 South Korea Glucagon-like Peptide-1 (GLP-1) Market by Value
4.3.9 Rest of Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market by Value
4.4 Latin America Glucagon-like Peptide-1 (GLP-1) Market: An Analysis
4.4.1 Latin America Glucagon-like Peptide-1 (GLP-1) Market: An Overview
4.4.2 Latin America Glucagon-like Peptide-1 (GLP-1) Market by Value
4.5 Middle East & Africa Glucagon-like Peptide-1 (GLP-1) Market: An Analysis
4.5.1 Middle East & Africa Glucagon-like Peptide-1 (GLP-1) Market: An Overview
4.5.2 Middle East & Africa Glucagon-like Peptide-1 (GLP-1) Market by Value
5. IMPACT OF COVID
5.1 Impact of COVID-19
5.1.1 Impact of COVID-19 on Healthcare
5.1.2 Impact of COVID-19 on Glucagon-like Peptide-1 (GLP-1) Market
6. MARKET DYNAMICS
6.1 Growth Driver
6.1.1 Rising Cases of Diabetes
6.1.2 Rising Cases of Obesity
6.1.3 Rapid Urbanization
6.1.4 Increasing Healthcare Expenditure
6.1.5 Increasing Aging Population
6.2 Challenges
6.2.1 Short Half-Life of Glucagon-like Peptide 1 (GLP-1) Receptor Agonists
6.2.2 Unknown Severe Side Effects
6.3 Market Trends
6.3.1 Potential Clinical Application of GLP-1 Receptor Agonists For the Treatment of NASH
6.3.2 Surge in Research & Development in Pharmaceutical Sector
6.3.3 New Product Launches
6.3.4 Expanding Reimbursement Landscape
7. COMPETITIVE LANDSCAPE
7.1 Global Glucagon-like Peptide 1 (GLP-1) Players by Market Share
7.2 Global Glucagon-like Peptide 1 (GLP-1) Market Players: Product Comparison
8. COMPANY PROFILES
8.1 Sanofi
8.1.1 Business Overview
8.1.2 Operating Segments
8.1.3 Business Strategies
8.2 Pfizer Inc.
8.2.1 Business Overview
8.2.2 Operating Segments
8.2.3 Business Strategies
8.3 AstraZeneca PLC
8.3.1 Business Overview
8.3.2 Operating Regions
8.3.3 Business Strategy
8.4 Eli Lilly and Company
8.4.1 Business Overview
8.4.2 Operating Products
8.4.3 Business Strategy
8.5 Novo Nordisk A/S
8.5.1 Business Overview
8.5.2 Operating Segments
8.5.3 Business Strategy
8.6 Shanghai Benemae Pharmaceutical Corporation
8.6.1 Business Overview
8.6.2 Business Strategy
8.7 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
8.7.1 Business Overview
8.7.2 Business Strategy
2. INTRODUCTION
2.1 Glucagon-like Peptide-1 (GLP-1): An Overview
2.1.1 Definition of Glucagon-like Peptide-1 (GLP-1)
2.1.2 Types of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist
2.2 Glucagon-like Peptide-1 (GLP-1) Segmentation: An Overview
2.2.1 Glucagon-like Peptide-1 (GLP-1) Segmentation
3. GLOBAL MARKET ANALYSIS
3.1 Global Glucagon-like Peptide-1 (GLP-1) Market: An Analysis
3.1.1 Global Glucagon-like Peptide-1 (GLP-1) Market: An Overview
3.1.2 Global Glucagon-like Peptide-1 (GLP-1) Market by Value
3.1.3 Global Glucagon-like Peptide-1 (GLP-1) Market by Product (Trulicity, Ozempic, Victoza, Rybelsus and Other GLP 1 Products)
3.1.4 Global Glucagon-like Peptide-1 (GLP-1) Market by Route of Administration (Injectable and Oral Medication)
3.1.5 Global Glucagon-like Peptide-1 (GLP-1) Market by Region (North America, Europe, Asia Pacific, Latin America and Middle East & Africa)
3.2 Global Glucagon-like Peptide-1 (GLP-1) Market: Product Analysis
3.2.1 Global Glucagon-like Peptide-1 (GLP-1) Market by Product: An Overview
3.2.2 Global Trulicity GLP-1 Market by Value
3.2.3 Global Ozempic GLP-1 Market by Value
3.2.4 Global Victoza GLP-1 Market by Value
3.2.5 Global Rybelsus GLP-1 Market by Value
3.2.6 Global Other GLP-1 Products Market by Value
4. REGIONAL MARKET ANALYSIS
4.1 North America Glucagon-like Peptide-1 (GLP-1) Market: An Analysis
4.1.1 North America Glucagon-like Peptide-1 (GLP-1) Market: An Overview
4.1.2 North America Glucagon-like Peptide-1 (GLP-1) Market by Value
4.1.3 North America Glucagon-like Peptide-1 (GLP-1) Market by Region (The US, Canada, and Mexico)
4.1.4 The US Glucagon-like Peptide-1 (GLP-1) Market by Value
4.1.5 The US Glucagon-like Peptide-1 (GLP-1) Market by Route of Administration (Injectable and Oral Medication)
4.1.6 Canada Glucagon-like Peptide-1 (GLP-1) Market by Value
4.1.7 Mexico Glucagon-like Peptide-1 (GLP-1) Market by Value
4.2 Europe Glucagon-like Peptide-1 (GLP-1) Market: An Analysis
4.2.1 Europe Glucagon-like Peptide-1 (GLP-1) Market: An Overview
4.2.2 Europe Glucagon-like Peptide-1 (GLP-1) Market by Value
4.2.3 Europe Glucagon-like Peptide-1 (GLP-1) Market by Region (Germany, The UK, France, Italy, Spain, and Rest of the Europe)
4.2.4 Germany Glucagon-like Peptide-1 (GLP-1) Market by Value
4.2.5 The UK Glucagon-like Peptide-1 (GLP-1) Market by Value
4.2.6 France Glucagon-like Peptide-1 (GLP-1) Market by Value
4.2.7 Italy Glucagon-like Peptide-1 (GLP-1) Market by Value
4.2.8 Spain Glucagon-like Peptide-1 (GLP-1) Market by Value
4.2.9 Rest of Europe Glucagon-like Peptide-1 (GLP-1) Market by Value
4.3 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market: An Analysis
4.3.1 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market: An Overview
4.3.2 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market by Value
4.3.3 Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market by Region (China, Japan, India, Australia, South Korea, and Rest of the Asia Pacific)
4.3.4 China Glucagon-like Peptide-1 (GLP-1) Market by Value
4.3.5 Japan Glucagon-like Peptide-1 (GLP-1) Market by Value
4.3.6 India Glucagon-like Peptide-1 (GLP-1) Market by Value
4.3.7 Australia Glucagon-like Peptide-1 (GLP-1) Market by Value
4.3.8 South Korea Glucagon-like Peptide-1 (GLP-1) Market by Value
4.3.9 Rest of Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market by Value
4.4 Latin America Glucagon-like Peptide-1 (GLP-1) Market: An Analysis
4.4.1 Latin America Glucagon-like Peptide-1 (GLP-1) Market: An Overview
4.4.2 Latin America Glucagon-like Peptide-1 (GLP-1) Market by Value
4.5 Middle East & Africa Glucagon-like Peptide-1 (GLP-1) Market: An Analysis
4.5.1 Middle East & Africa Glucagon-like Peptide-1 (GLP-1) Market: An Overview
4.5.2 Middle East & Africa Glucagon-like Peptide-1 (GLP-1) Market by Value
5. IMPACT OF COVID
5.1 Impact of COVID-19
5.1.1 Impact of COVID-19 on Healthcare
5.1.2 Impact of COVID-19 on Glucagon-like Peptide-1 (GLP-1) Market
6. MARKET DYNAMICS
6.1 Growth Driver
6.1.1 Rising Cases of Diabetes
6.1.2 Rising Cases of Obesity
6.1.3 Rapid Urbanization
6.1.4 Increasing Healthcare Expenditure
6.1.5 Increasing Aging Population
6.2 Challenges
6.2.1 Short Half-Life of Glucagon-like Peptide 1 (GLP-1) Receptor Agonists
6.2.2 Unknown Severe Side Effects
6.3 Market Trends
6.3.1 Potential Clinical Application of GLP-1 Receptor Agonists For the Treatment of NASH
6.3.2 Surge in Research & Development in Pharmaceutical Sector
6.3.3 New Product Launches
6.3.4 Expanding Reimbursement Landscape
7. COMPETITIVE LANDSCAPE
7.1 Global Glucagon-like Peptide 1 (GLP-1) Players by Market Share
7.2 Global Glucagon-like Peptide 1 (GLP-1) Market Players: Product Comparison
8. COMPANY PROFILES
8.1 Sanofi
8.1.1 Business Overview
8.1.2 Operating Segments
8.1.3 Business Strategies
8.2 Pfizer Inc.
8.2.1 Business Overview
8.2.2 Operating Segments
8.2.3 Business Strategies
8.3 AstraZeneca PLC
8.3.1 Business Overview
8.3.2 Operating Regions
8.3.3 Business Strategy
8.4 Eli Lilly and Company
8.4.1 Business Overview
8.4.2 Operating Products
8.4.3 Business Strategy
8.5 Novo Nordisk A/S
8.5.1 Business Overview
8.5.2 Operating Segments
8.5.3 Business Strategy
8.6 Shanghai Benemae Pharmaceutical Corporation
8.6.1 Business Overview
8.6.2 Business Strategy
8.7 Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
8.7.1 Business Overview
8.7.2 Business Strategy
LIST OF FIGURES
Figure 1: Types of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist
Figure 2: Glucagon-like Peptide-1 (GLP-1) Segmentation by Product
Figure 3: Global Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Billion)
Figure 4: Global Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 5: Global Glucagon-like Peptide-1 (GLP-1) Market by Product; 2021 (Percentage, %)
Figure 6: Global Glucagon-like Peptide-1 (GLP-1) Market by Route of Administration; 2021 (Percentage, %)
Figure 7: Global Glucagon-like Peptide-1 (GLP-1) Market by Region; 2021 (Percentage, %)
Figure 8: Global Trulicity GLP-1 Market by Value; 2017-2021 (US$ Billion)
Figure 9: Global Trulicity GLP-1 Market by Value; 2022-2027 (US$ Billion)
Figure 10: Global Ozempic GLP-1 Market by Value; 2017-2021 (US$ Billion)
Figure 11: Global Ozempic GLP-1 Market by Value; 2022-2027 (US$ Billion)
Figure 12: Global Victoza GLP-1 Market by Value; 2017-2021 (US$ Billion)
Figure 13: Global Victoza GLP-1 Market by Value; 2022-2027 (US$ Billion)
Figure 14: Global Rybelsus GLP-1 Market by Value; 2017-2021 (US$ Million)
Figure 15: Global Rybelsus GLP-1 Market by Value; 2022-2027 (US$ Billion)
Figure 16: Global Other GLP-1 Products Market by Value; 2017-2021 (US$ Billion)
Figure 17: Global Other GLP-1 Products Market by Value; 2022-2027 (US$ Billion)
Figure 18: North America Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Billion)
Figure 19: North America Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 20: North America Glucagon-like Peptide-1 (GLP-1) Market by Region; 2021 (Percentage, %)
Figure 21: The US Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Billion)
Figure 22: The US Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 23: The US Glucagon-like Peptide-1 (GLP-1) Market by Route of Administration; 2021 (Percentage, %)
Figure 24: Canada Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 25: Canada Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 26: Mexico Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 27: Mexico Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 28: Europe Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Billion)
Figure 29: Europe Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 30: Europe Glucagon-like Peptide-1 (GLP-1) Market by Region; 2021 (Percentage, %)
Figure 31: Germany Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Billion)
Figure 32: Germany Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 33: The UK Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 34: The UK Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 35: France Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 36: France Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 37: Italy Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 38: Italy Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 39: Spain Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 40: Spain Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 41: Rest of Europe Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 42: Rest of Europe Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 43: Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Billion)
Figure 44: Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 45: Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market by Region; 2021 (Percentage, %)
Figure 46: China Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 47: China Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 48: Japan Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 49: Japan Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 50: India Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 51: India Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 52: Australia Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 53: Australia Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 54: South Korea Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 55: South Korea Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 56: Rest of Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 57: Rest of Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 58: Latin America Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 59: Latin America Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 60: Middle East & Africa Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 61: Middle East & Africa Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 62: Global Number of People with Diabetes in Adults (20–79 Years) by Region; 2021 & 2045 (Million)
Figure 63: Global Numbers Of People with Obesity and Severe Obesity, 2010-2030 (Million)
Figure 64: Global Urban Population; 2017-2021 (Percentage, %)
Figure 65: The US, Sweden and Norway Health Spending Per Capita; 2017-2021 (US$ Million)
Figure 66: Global Percentage of Population Aged 65 Years or Over; 2022, 2030 & 2050 (Percentage, %)
Figure 67: NASH Prevalence and Diagnosed Cases; 2021 & 2030 (Million)
Figure 68: Global Pharmaceutical Research and Development Spending; 2019-2028 (US$ Billion)
Figure 69: Global Glucagon-like Peptide 1 (GLP-1) Players by Market Share; 2021 (Percentage, %)
Figure 70: Sanofi Net Sales by Segments; 2021 (Percentage, %)
Figure 71: Pfizer Inc. Revenues by Operating Segments; 2021 (Percentage, %)
Figure 72: AstraZeneca PLC Revenue by Geographical Region; 2021 (Percentage, %)
Figure 73: Eli Lilly and Company Revenue by Products; 2021 (Percentage, %)
Figure 74: Novo Nordisk A/S Net Sales by Segment; 2021 (Percentage, %)
Table 1: Global Glucagon-like Peptide 1 (GLP-1) Market Players: Product Comparison
Figure 1: Types of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist
Figure 2: Glucagon-like Peptide-1 (GLP-1) Segmentation by Product
Figure 3: Global Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Billion)
Figure 4: Global Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 5: Global Glucagon-like Peptide-1 (GLP-1) Market by Product; 2021 (Percentage, %)
Figure 6: Global Glucagon-like Peptide-1 (GLP-1) Market by Route of Administration; 2021 (Percentage, %)
Figure 7: Global Glucagon-like Peptide-1 (GLP-1) Market by Region; 2021 (Percentage, %)
Figure 8: Global Trulicity GLP-1 Market by Value; 2017-2021 (US$ Billion)
Figure 9: Global Trulicity GLP-1 Market by Value; 2022-2027 (US$ Billion)
Figure 10: Global Ozempic GLP-1 Market by Value; 2017-2021 (US$ Billion)
Figure 11: Global Ozempic GLP-1 Market by Value; 2022-2027 (US$ Billion)
Figure 12: Global Victoza GLP-1 Market by Value; 2017-2021 (US$ Billion)
Figure 13: Global Victoza GLP-1 Market by Value; 2022-2027 (US$ Billion)
Figure 14: Global Rybelsus GLP-1 Market by Value; 2017-2021 (US$ Million)
Figure 15: Global Rybelsus GLP-1 Market by Value; 2022-2027 (US$ Billion)
Figure 16: Global Other GLP-1 Products Market by Value; 2017-2021 (US$ Billion)
Figure 17: Global Other GLP-1 Products Market by Value; 2022-2027 (US$ Billion)
Figure 18: North America Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Billion)
Figure 19: North America Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 20: North America Glucagon-like Peptide-1 (GLP-1) Market by Region; 2021 (Percentage, %)
Figure 21: The US Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Billion)
Figure 22: The US Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 23: The US Glucagon-like Peptide-1 (GLP-1) Market by Route of Administration; 2021 (Percentage, %)
Figure 24: Canada Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 25: Canada Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 26: Mexico Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 27: Mexico Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 28: Europe Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Billion)
Figure 29: Europe Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 30: Europe Glucagon-like Peptide-1 (GLP-1) Market by Region; 2021 (Percentage, %)
Figure 31: Germany Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Billion)
Figure 32: Germany Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 33: The UK Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 34: The UK Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 35: France Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 36: France Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 37: Italy Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 38: Italy Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 39: Spain Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 40: Spain Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 41: Rest of Europe Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 42: Rest of Europe Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 43: Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Billion)
Figure 44: Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 45: Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market by Region; 2021 (Percentage, %)
Figure 46: China Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 47: China Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 48: Japan Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 49: Japan Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 50: India Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 51: India Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 52: Australia Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 53: Australia Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 54: South Korea Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 55: South Korea Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 56: Rest of Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 57: Rest of Asia Pacific Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Million)
Figure 58: Latin America Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 59: Latin America Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 60: Middle East & Africa Glucagon-like Peptide-1 (GLP-1) Market by Value; 2017-2021 (US$ Million)
Figure 61: Middle East & Africa Glucagon-like Peptide-1 (GLP-1) Market by Value; 2022-2027 (US$ Billion)
Figure 62: Global Number of People with Diabetes in Adults (20–79 Years) by Region; 2021 & 2045 (Million)
Figure 63: Global Numbers Of People with Obesity and Severe Obesity, 2010-2030 (Million)
Figure 64: Global Urban Population; 2017-2021 (Percentage, %)
Figure 65: The US, Sweden and Norway Health Spending Per Capita; 2017-2021 (US$ Million)
Figure 66: Global Percentage of Population Aged 65 Years or Over; 2022, 2030 & 2050 (Percentage, %)
Figure 67: NASH Prevalence and Diagnosed Cases; 2021 & 2030 (Million)
Figure 68: Global Pharmaceutical Research and Development Spending; 2019-2028 (US$ Billion)
Figure 69: Global Glucagon-like Peptide 1 (GLP-1) Players by Market Share; 2021 (Percentage, %)
Figure 70: Sanofi Net Sales by Segments; 2021 (Percentage, %)
Figure 71: Pfizer Inc. Revenues by Operating Segments; 2021 (Percentage, %)
Figure 72: AstraZeneca PLC Revenue by Geographical Region; 2021 (Percentage, %)
Figure 73: Eli Lilly and Company Revenue by Products; 2021 (Percentage, %)
Figure 74: Novo Nordisk A/S Net Sales by Segment; 2021 (Percentage, %)
Table 1: Global Glucagon-like Peptide 1 (GLP-1) Market Players: Product Comparison
